Horizon Medical Products Will Relieve Debt Load With IPO Proceeds
This article was originally published in The Gray Sheet
Executive Summary
Horizon Medical Products is earmarking the lion's share of $31.6 mil. in anticipated net proceeds from a planned initial public offering to settle outstanding debt related to the firm's July 15 acquisition of Pfizer's Strato/Infusaid business and its October 1995 purchase of NeoStar Medical Technologies.
You may also be interested in...
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.